FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings.
All of FibroGen’s therapeutic candidates have been internally developed based on FibroGen’s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
The 2016 Albert Lasker Basic Medical Research Award honors three physician-scientists for their discovery of the HIF pathway.